Tenofovir alafenamide
Vemlidy (tenofovir alafenamide) is a small molecule pharmaceutical. Tenofovir alafenamide was first approved as Vemlidy on 2016-11-10. It is used to treat chronic hepatitis b in the USA. It has been approved in Europe to treat hepatitis b. Genvoya's patents are valid until 2032-08-15 (FDA).
| Trade Name | Vemlidy |
|---|---|
| Common Name | Tenofovir alafenamide |
| Indication | chronic hepatitis b, hepatitis b |
| Drug Class | Antivirals |
